NCT01558778
Withdrawn
N/A
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
ConditionsAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous LeukemiaChronic Eosinophilic LeukemiaChronic Myelomonocytic LeukemiaChronic Neutrophilic LeukemiaChronic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesDisseminated NeuroblastomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Adult Burkitt LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Mixed Cell LymphomaNoncontiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaNoncontiguous Stage II Adult Immunoblastic Large Cell LymphomaNoncontiguous Stage II Adult Lymphoblastic LymphomaNoncontiguous Stage II Grade 1 Follicular LymphomaNoncontiguous Stage II Grade 2 Follicular LymphomaNoncontiguous Stage II Grade 3 Follicular LymphomaNoncontiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Marginal Zone LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaPlasma Cell NeoplasmPoor Prognosis Metastatic Gestational Trophoblastic TumorPreviously Treated Myelodysplastic SyndromesPrimary MyelofibrosisProlymphocytic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Malignant Testicular Germ Cell TumorRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent NeuroblastomaRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesSplenic Marginal Zone LymphomaStage II Ovarian Epithelial CancerStage II Ovarian Germ Cell TumorStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage III Adult Diffuse Mixed Cell LymphomaStage III Adult Diffuse Small Cleaved Cell LymphomaStage III Adult Hodgkin LymphomaStage III Adult Immunoblastic Large Cell LymphomaStage III Adult Lymphoblastic LymphomaStage III Chronic Lymphocytic LeukemiaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Malignant Testicular Germ Cell TumorStage III Mantle Cell LymphomaStage III Marginal Zone LymphomaStage III Ovarian Epithelial CancerStage III Ovarian Germ Cell TumorStage III Small Lymphocytic LymphomaStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaStage IV Adult Diffuse Mixed Cell LymphomaStage IV Adult Diffuse Small Cleaved Cell LymphomaStage IV Adult Hodgkin LymphomaStage IV Adult Immunoblastic Large Cell LymphomaStage IV Adult Lymphoblastic LymphomaStage IV Breast CancerStage IV Chronic Lymphocytic LeukemiaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell LymphomaStage IV Marginal Zone LymphomaStage IV Ovarian Epithelial CancerStage IV Ovarian Germ Cell TumorStage IV Small Lymphocytic Lymphoma
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia
- Sponsor
- Roswell Park Cancer Institute
- Primary Endpoint
- Adherence with treatment
- Status
- Withdrawn
- Last Updated
- 13 years ago
Overview
Brief Summary
This pilot clinical trial studies mechanical stimulation in preventing bone density loss in patients undergoing donor stem cell transplant. Mechanical stimulation may limit, prevent, or reverse bone loss, increase muscle and cardiac performance, and improve overall health
Detailed Description
PRIMARY OBJECTIVES: I. To determine the feasibility of a mechanical stimulation regimen in hematopoietic cell transplant (HCT) patients. SECONDARY OBJECTIVES: I. To evaluate the data collection tools to prepare for a larger phase II trial. OUTLINE: Patients undergo mechanical stimulation over 20 minutes once daily (QD) beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Meet eligibility criteria for first allogeneic HCT, and are scheduled to undergo allogeneic HCT
- •Pre-transplant Karnofsky Performance Status (KPS) \>= 70
- •Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria
- •Any prior allogeneic HCT
- •Pre-transplant weight \>= 280 lbs
- •Body mass index (BMI) \< l8kg/m\^2
- •Human leukocyte antigen (HLA)-mismatched HCT
- •Cord blood transplant
- •Osteopenia or osteoporosis (T-score =\< -1.0)
- •Multiple myeloma diagnosis
- •Any prior history of a central nervous system (CNS) hemorrhage
- •Currently treated with a therapeutic dose of anti-coagulation for a recent pulmonary embolism or deep vein thrombosis
- •Current or previous bisphosphonate use
Outcomes
Primary Outcomes
Adherence with treatment
Time Frame: From hospital admission to 100 days post-HCT
Effective data collection tools and data points
Time Frame: From hospital admission to 100 days post-HCT
Refinement of mechanical stimulation protocol
Time Frame: From hospital admission to 100 days post-HCT
Best time of day for treatment, staff involvement, etc.
Similar Trials
Completed
Phase 1
Mechanical Bone Stimulation and Adenosine 5'-Triphosphate (ATP) Release in HumansOsteoporosisNCT01130428Maastricht University Medical Center10
Completed
Phase 3
Improving Low Bone Mass With Vibration Therapy in Adolescent Idiopathic Scoliosis (AIS)ScoliosisBone Diseases, MetabolicNCT01108211Chinese University of Hong Kong149
Completed
N/A
Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia NervosaAnorexia NervosaNCT01100567Boston Children's Hospital101
Completed
N/A
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRDRenal OsteodystrophyNCT00364234National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30
Completed
Phase 3
Heartland Osteoporosis Prevention StudyOsteopeniaNCT02186600University of Nebraska276